Sign in
Taking people in NetherlandsPhase 1

Early safety study of LCA-0321 in people with Graves disease

Tests LCA-0321 in adults who have Graves disease.

Key facts

Who runs it
Lycia Therapeutics Inc.
Where
's-Hertogenbosch, Groningen, and Rotterdam, NetherlandsSee the 3 sites
Registry title
Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321
Status
Recruiting
Phase
Phase 1
People taking part
22 people, planned
Started
2 Apr 2026
Expected to end
1 Sept 2028
Type of study
Interventional
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves disease for an early study of single and repeated rising doses of LCA-0321.

Age
18 years and older
Sex
All sexes

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Netherlands

  • Brain Research Center Den Bosch B.V.'s-Hertogenbosch, NetherlandsTaking people
  • CTC Netherlands B.V.Groningen, NetherlandsTaking people
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Early safety study of LCA-0321 in people with Graves diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
30 September 2026